{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/TLX",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Telix Pharmaceuticals Ltd (NASDAQ: TLX) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Telix Pharmaceuticals Ltd, listed on NASDAQ under ticker TLX, with ISIN US87961M1053. The LEI is not on the record, as no GLEIF record with the exact legal name in jurisdiction US-C3 was found. The security type is Non-operating entity type (other), the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Australia. The issuer is listed and not halted.\n\n## The disclosure read\n\nThe record holds 50 filings in the twelve months from 2025-11-08 to 2026-11-08, across 38 filing days. The filings are 33 results, 13 directors' dealings, 3 regulatory filings and 1 prospectus. The median gap between filing days is 6 days. The latest filing is a results filing dated 2026-10-29, 10 days before the record date of 2026-11-08, so latency is 10 days. The NASDAQ exchange median is 6.0 days for cadence and 5.0 days for latency, across 4359 issuers, with a median of 52 filings. The 2834 Pharmaceutical Preparations sector median is 6.0 days for cadence and 4.0 days for latency, across 526 issuers, with a median of 63.0 filings.\n\n## Auditor\n\nThe auditor is not on the record, as the latest annual report cover carries no dei:AuditorName tag, and foreign private issuers and older filings carry none. The auditor's location is not on the record. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nNo research houses were found on the issuer's investor-relations page.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds sealed years 2024, 2025 and 2026 for the issuer. The market's vintage is sealed, with the earliest sealed date of the US market at 2021-01-04. The live record began on 2026-09-12.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)\n- https://data.sec.gov/submissions/CIK0002007191.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/TLX (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/TLX (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "market": "US",
    "reason": "no dei:AuditorName tag on the latest annual report cover (foreign private issuers and older filings carry none)",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "US",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "US",
    "state": "not_on_record"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/TLX",
  "coverage": {
   "count": 0,
   "houses": [],
   "pages_checked": [
    {
     "page": "https://ir.telixpharma.com/stock/analyst-coverage",
     "result": "not readable by this rail (403)"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": null,
   "state": "none_found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "directors_dealings": 13,
    "prospectus": 1,
    "regulatory_filing": 3,
    "results": 33
   },
   "cadence_median_gap_days": 6,
   "filing_days": 38,
   "filings": 50,
   "latency_days": 10,
   "latest": [
    {
     "category": "6-K",
     "date": "2026-10-29",
     "source": "https://www.sec.gov/Archives/edgar/data/2007191/000162828026068291/noticeofmeeting.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-10-21",
     "source": "https://www.sec.gov/Archives/edgar/data/2007191/000162828026066581/q32026resultsannouncement.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-09-30",
     "source": "https://www.sec.gov/Archives/edgar/data/2007191/000162828026063875/telix-6kbipassgainsfdafast.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "6-K",
     "date": "2026-09-21",
     "source": "https://www.sec.gov/Archives/edgar/data/2007191/000162828026062813/telix-6ktelixanditmjoinfor.htm",
     "title": "6-K — 6-K",
     "type": "results"
    },
    {
     "category": "4",
     "date": "2026-09-14",
     "source": "https://www.sec.gov/Archives/edgar/data/2007191/000162828026061944/xslF345X06/wk-form4_1789428011.xml",
     "title": "4 — FORM 4",
     "type": "directors_dealings"
    }
   ],
   "latest_filing_date": "2026-10-29",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/TLX",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "read_by": "SEC Fails-to-Deliver data (CUSIP for the symbol) · ISIN = US + CUSIP + ISO 6166 check digit",
    "read_date": "2026-10-14",
    "read_date_basis": "last_seen",
    "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data",
    "state": "sourced",
    "value": "US87961M1053"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002007191.json",
    "state": "sourced",
    "value": "Australia"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-C3",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002007191.json",
    "state": "sourced",
    "value": "Telix Pharmaceuticals Ltd"
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002007191.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0002007191.json",
    "state": "sourced",
    "value": "Non-operating entity type (other)"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "TLX"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:1060eea3c777eb29dc0e3ad5f492f38a7360083431728644658e4a174ac2de95",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/TLX",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:1060eea3c777eb29dc0e3ad5f492f38a7360083431728644658e4a174ac2de95",
 "path": "/us/NASDAQ/TLX",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Telix Pharmaceuticals Ltd, listed on NASDAQ under ticker TLX, with ISIN US87961M1053. The LEI is not on the record, as no GLEIF record with the exact legal name in jurisdiction US-C3 was found. The security type is Non-operating entity type (other), the segment is not on the record, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is Australia. The issuer is listed and not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 50 filings in the twelve months from 2025-11-08 to 2026-11-08, across 38 filing days. The filings are 33 results, 13 directors' dealings, 3 regulatory filings and 1 prospectus. The median gap between filing days is 6 days. The latest filing is a results filing dated 2026-10-29, 10 days before the record date of 2026-11-08, so latency is 10 days. The NASDAQ exchange median is 6.0 days for cadence and 5.0 days for latency, across 4359 issuers, with a median of 52 filings. The 2834 Pharmaceutical Preparations sector median is 6.0 days for cadence and 4.0 days for latency, across 526 issuers, with a median of 63.0 filings.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor is not on the record, as the latest annual report cover carries no dei:AuditorName tag, and foreign private issuers and older filings carry none. The auditor's location is not on the record. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "No research houses were found on the issuer's investor-relations page.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds sealed years 2024, 2025 and 2026 for the issuer. The market's vintage is sealed, with the earliest sealed date of the US market at 2021-01-04. The live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.isin",
   "source": "https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0002007191.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/TLX"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/TLX"
  }
 ],
 "title": "Telix Pharmaceuticals Ltd (TLX) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}